RE: [NMusers] ASCO and pharmacometrics

From: Lowe, Phil <phil.lowe_at_novartis.com>
Date: Thu, 7 Apr 2016 14:49:26 +0000

I would echo Pascal’s point. Getting pharmacometric work into large clinical conferences is not straightforward. It can be done (see link) http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract but note where I was in the author list as the sole modeller. It helps to work closely with the clinicians on the messaging. That said, it was fun at the meeting, explaining the data and model curves to clinicians with them asking how such knowledge could impact their patients. An eye-opener. Keep trying Naoto!

All the best, Phil

Philip J Lowe PhD
Executive Director Pharmacometrics Scientist
Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
4056 Basel, Switzerland
Phone: +41 61 324 4676
phil.lowe_at_novartis.com<mailto:phil.lowe_at_novartis.com>

From: owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com] On Behalf Of Pascal Girard
Sent: 06 April 2016 10:39
To: Naoto Hayashi; jgrevel_at_btconnect.com
Cc: nmusers
Subject: RE: [NMusers] ASCO and pharmacometrics

Dear Naoto,

In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is our ”champion” !

I got one accepted on model for Exp-Tumor Size – OS at European Cancer Congress 2013 . But I can tell you that a medical writer rewrote it entirely and it took 1 month to get it reviewed and corrected by clinicians challenging every comma and p-value.

To give you an idea of the respective size of the meetings: ACOP N=500, PAGE N>600, ECC N> 10,000, ASCO N>20,000.

So the advice I would give, is just improve the quality and readability of our abstract and it will make it. By readability, I mean show it to an oncologist clinician. If he does not understand, rewrite it with the help of a medical writer …

With best regards / Mit freundlichen Grüßen / Cordialement

Pascal
Received on Thu Apr 07 2016 - 10:49:26 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:49:48 EDT